ReviewInternational journal of clinical oncology2012
Current status of DILD in molecular targeted therapies.
Review in International journal of clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.Japanese journal of clinical oncology · 2014Trial
- Case Report: Osimertinib-induced acute interstitial lung disease.Frontiers in pharmacology · 2025Article
- Regional diversity in drug-induced lung diseases among the USA, European Union, and Japan.Frontiers in medicine · 2024Article
- Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges.ERJ open research · 2022Review
- Chemotherapy-Associated Pulmonary Toxicity-Case Series from a Single Center.South Asian journal of cancer · 2021Article
- Efficacy and safety of low-dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1.Clinical case reports · 2021Article
- Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.Breast cancer (Tokyo, Japan) · 2021Article
- Imaging Biomarkers in Animal Models of Drug-Induced Lung Injury: A Systematic Review.Journal of clinical medicine · 2020Review
- Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers.Journal of thoracic disease · 2020Article
- Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.Targeted oncology · 2019Article
- Rapidly progressing programmed cell death 1 inhibitor-related pneumonitis in a hemodialytic patient with metastatic renal cell carcinoma.IJU case reports · 2019Article
- [EGFR-TKI ADR Management Chinese Expert Consensus].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Article
- Nivolumab-induced interstitial lung disease in a patient with gastric cancer.Oxford medical case reports · 2019Article
- A case of maoto-induced interstitial pneumonia.Journal of thoracic disease · 2018Article
- Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17.Therapeutics and clinical risk management · 2018Article
- Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study.International journal of clinical oncology · 2015Article
- Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients.Journal of radiation research · 2015Article
- Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study.Therapeutics and clinical risk management · 2015Article
- Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.Cancer science · 2014Article
- Sarcoidosis associated with oxaliplatin-based chemotherapy for colorectal cancer.Case reports in oncological medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular targeted drugs have become the mainstream for cancer therapy, and they have contributed to improving the outcome for cancer patients. On the other hand, molecular targeted drugs are associated with a variety of adverse drug reactions. Drug-induced interstitial lung disease (DILD) is a typical adverse drug reaction that has been an important problem with regard to safety management during cancer treatment. In the past, there was a lack of detailed and accurate epidemiological data about DILD. However, most of the molecular targeted drugs have been subject to all-case post-marketing surveillance since gefitinib-induced ILD became a concern. These surveillance data present useful information about DILD, such as frequency of adverse events, mortality, and risk factors, and as a result, the epidemiological profile of DILD associated with molecular targeted drugs has become apparent during the past decade. Further, it has been considered that the principal management for DILD is early detection and cessation of the suspected cause. However, ILD associated with everolimus and temsirolimus requires unusual management; i.e., patients with asymptomatic ILD are allowed to continue treatment with everolimus or temsirolimus, and even after symptomatic ILD, both everolimus and temsirolimus are allowed to be readministered after the resolution of ILD. As a result of the collected data, a change has begun in the field of DILD associated with molecular targeted drugs. The features of DILD can differ for each drug, and clinicians should thus keep this information about DILD in mind while treating patients.
Indexed as
Identifiers
23152005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.